Company / Shareholders' Equity
LENZ Therapeutics, Inc. Shareholders' Equity History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$284.3M
FY2025
5-year range
-$92.7M / $384.1M
FY2021-FY2025
Trend
+39.3%
vs FY2024
Sector context
#138 of 213
Health Care
What the data says
At $284M, LENZ Therapeutics, Inc.'s shareholders' equity ranks #138 of 213 in the Health Care sector. Improved from -$93M to $284M over the past 2 years.
Based on SEC 10-K filings.
$284M in FY2025.
Improved from -$93M to $284M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#138 of 213 in Health CareTop 65% of 213This company $284.3M Sector average $2.5B
▼
-88.8% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity increased 39.3% year-over-year.
- Ranks #138 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
- Lowest shareholders' equity in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $284.3M | +39.3% |
| FY2024 | $204.1M | +320.1% |
| FY2023 | -$92.7M | -283.6% |
| FY2022 | -$24.2M | -106.3% |
| FY2021 | $384.1M | +687.2% |
| FY2020 | -$65.4M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026